No Data
No Data
Gilead and Vertex Pharma Named Among Biotech's Tariff Safe Havens
Barclays Maintains Overweight on Exact Sciences, Raises Price Target to $75
What to Expect From Neurocrine Biosciences's Earnings
Earnings Outlook For Vertex Pharmaceuticals
Liquidia Surges 15% as Court Clears Way for Yutrepia Launch
Peering Into Natera's Recent Short Interest